表紙
市場調査レポート

呼吸抑制:パイプライン製品の分析

Respiratory Depression - Pipeline Review, H2 2015

発行 Global Markets Direct 商品コード 192804
出版日 ページ情報 英文 40 Pages
即納可能
価格
本日の銀行送金レート: 1USD=106.71円で換算しております。
Back to Top
呼吸抑制:パイプライン製品の分析 Respiratory Depression - Pipeline Review, H2 2015
出版日: 2015年09月30日 ページ情報: 英文 40 Pages
概要

呼吸抑制とは、呼吸障害の状態−−十分な量の酸素を取り込み、二酸化炭素を排出する能力が低下した状態−−を指します。その結果、頻繁に息切れし、胸が締め付けられるような感覚を味わいます。その原因として、呼吸器疾患やオピオイドの使用など、様々な要素が考えられます。オピオイドは主に疼痛治療に使われますが、呼吸抑制を初めとする様々な副作用を伴っています。

当レポートでは、世界各国での呼吸抑制治療用のパイプライン製品の開発状況について分析し、製品開発・上市の最新動向や、治験の各段階にある製品の一覧、主要企業のプロファイル、主な薬剤の概要、最新の業界動向などの情報をお届けします。

目次

イントロダクション

  • 分析範囲

呼吸抑制の概要

治療薬の開発

  • 呼吸抑制向けパイプライン製品:概要
  • 呼吸抑制向けパイプライン製品:比較分析

各企業で開発中の呼吸抑制治療薬

パイプライン製品の概略

  • 治験段階の製品
  • 初期段階の製品
  • 不明確な段階にある製品

呼吸抑制治療薬:開発中の製品の一覧(企業別)

呼吸抑制治療薬の開発に従事している企業

  • Cortex Pharmaceuticals, Inc.
  • Galleon Pharmaceuticals

呼吸抑制:治療薬の評価

  • 単剤治療薬の場合
  • 標的別
  • 作用機序別
  • 投与方法別
  • 分子の種類別

薬剤のプロファイル

  • CX-1739
    • 製品概要
    • 機能メカニズム
    • 研究開発(R&D)の進展状況
  • GAL-021
  • CX-1942
  • CX-2007
  • CX-2076
  • GAL-021
  • 後継薬
  • 塩酸ドキサプラム
  • CX-1739

呼吸抑制治療薬:パイプライン製品の最新動向

呼吸抑制治療薬:開発が休止状態の製品

呼吸抑制関連製品の開発のマイルストーン

  • 注目すべき最新動向・プレスリリース(全5件)

付録

図表一覧

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: GMDHC7178IDB

Summary

Global Markets Direct's, 'Respiratory Depression - Pipeline Review, H2 2015', provides an overview of the Respiratory Depression's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Respiratory Depression, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Respiratory Depression and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Respiratory Depression
  • The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in the therapeutics development for Respiratory Depression and enlists all their major and minor projects
  • The report summarizes all the dormant and discontinued pipeline projects
  • A review of the Respiratory Depression products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • A detailed assessment of monotherapy and combination therapy pipeline projects
  • Coverage of the Respiratory Depression pipeline on the basis of target, MoA, route of administration and molecule type
  • Latest news and deals relating related to pipeline products

Reasons to buy

  • Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Identify and understand important and diverse types of therapeutics under development for Respiratory Depression
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Devise corrective measures for pipeline projects by understanding Respiratory Depression pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Respiratory Depression Overview
  • Therapeutics Development
    • Pipeline Products for Respiratory Depression - Overview
    • Pipeline Products for Respiratory Depression - Comparative Analysis
  • Respiratory Depression - Therapeutics under Development by Companies
  • Respiratory Depression - Pipeline Products Glance
    • Clinical Stage Products
    • Early Stage Products
  • Respiratory Depression - Products under Development by Companies
  • Respiratory Depression - Companies Involved in Therapeutics Development
    • Cortex Pharmaceuticals, Inc.
    • Galleon Pharmaceuticals
  • Respiratory Depression - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • CX-1739 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • CX-1942 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • CX-2007 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • CX-2076 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • GAL-021 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • tianeptine - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • Respiratory Depression - Recent Pipeline Updates
  • Respiratory Depression - Dormant Projects
  • Respiratory Depression - Product Development Milestones
    • Featured News & Press Releases
      • May 04, 2015: Cortex Pharmaceuticals Announces Publication of Research Results on the Use of Ampakines CX1739 in the Treatment of Respiratory Disorders
      • Sep 24, 2014: Cortex Pharmaceuticals Announces Phase 1 Funding by the National Institute of Drug Abuse, National Institutes of Health, Under the Small Business Innovation Research Funding Award Program
      • Feb 12, 2014: Revive Therapeutics Announces Encouraging Interim Results from Ongoing Phase 2a Proof-Of-Concept Study of REV-001 for the Prevention of Opioid-Induced Respiratory Depression
      • Sep 20, 2012: Galleon Pharma Reports Positive Results From Second Phase I Study Of GAL-021 For Treatment Of Respiratory Depression
      • May 07, 2012: Galleon Reports Positive Results From Phase I Study Of GAL-021 For Treatment Of Respiratory Depression
      • Aug 24, 2011: Cortex Receives US Patent For Use Of Ampakine Molecules To Treat Respiratory Depression
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Respiratory Depression, H2 2015
  • Number of Products under Development for Respiratory Depression - Comparative Analysis, H2 2015
  • Number of Products under Development by Companies, H2 2015
  • Comparative Analysis by Clinical Stage Development, H2 2015
  • Comparative Analysis by Early Stage Development, H2 2015
  • Products under Development by Companies, H2 2015
  • Respiratory Depression - Pipeline by Cortex Pharmaceuticals, Inc., H2 2015
  • Respiratory Depression - Pipeline by Galleon Pharmaceuticals, H2 2015
  • Assessment by Monotherapy Products, H2 2015
  • Number of Products by Stage and Target, H2 2015
  • Number of Products by Stage and Mechanism of Action, H2 2015
  • Number of Products by Stage and Route of Administration, H2 2015
  • Number of Products by Stage and Molecule Type, H2 2015
  • Respiratory Depression Therapeutics - Recent Pipeline Updates, H2 2015
  • Respiratory Depression - Dormant Projects, H2 2015

List of Figures

  • Number of Products under Development for Respiratory Depression, H2 2015
  • Number of Products under Development for Respiratory Depression - Comparative Analysis, H2 2015
  • Number of Products under Development by Companies, H2 2015
  • Comparative Analysis by Clinical Stage Development, H2 2015
  • Comparative Analysis by Early Stage Products, H2 2015
  • Assessment by Monotherapy Products, H2 2015
  • Number of Products by Top 10 Targets, H2 2015
  • Number of Products by Stage and Top 10 Targets, H2 2015
  • Number of Products by Top 10 Mechanism of Actions, H2 2015
  • Number of Products by Stage and Top 10 Mechanism of Actions, H2 2015
  • Number of Products by Top 10 Routes of Administration, H2 2015
  • Number of Products by Stage and Top 10 Routes of Administration, H2 2015
  • Number of Products by Stage and Top 10 Molecule Types, H2 2015
Back to Top